ATE113845T1 - Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung. - Google Patents

Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.

Info

Publication number
ATE113845T1
ATE113845T1 AT88104966T AT88104966T ATE113845T1 AT E113845 T1 ATE113845 T1 AT E113845T1 AT 88104966 T AT88104966 T AT 88104966T AT 88104966 T AT88104966 T AT 88104966T AT E113845 T1 ATE113845 T1 AT E113845T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
antibodies against
glycolipid antigens
against glycolipid
antigens
Prior art date
Application number
AT88104966T
Other languages
English (en)
Inventor
Zenon Steplewski
Hilary Koprowski
Magdalena Thurin
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE113845T1 publication Critical patent/ATE113845T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT88104966T 1987-03-27 1988-03-28 Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung. ATE113845T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/030,537 US4971792A (en) 1987-03-27 1987-03-27 Monoclonal antibodies against glycolipid antigens

Publications (1)

Publication Number Publication Date
ATE113845T1 true ATE113845T1 (de) 1994-11-15

Family

ID=21854682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88104966T ATE113845T1 (de) 1987-03-27 1988-03-28 Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.

Country Status (6)

Country Link
US (1) US4971792A (de)
EP (1) EP0285059B1 (de)
JP (1) JPS63279169A (de)
AT (1) ATE113845T1 (de)
CA (1) CA1303980C (de)
DE (1) DE3852054T2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US20020146410A1 (en) * 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
RU2208642C2 (ru) * 1992-05-22 2003-07-20 Новартис Аг МОНОКЛОНАЛЬНОЕ АНТИИДИОТИПИЧЕСКОЕ АНТИТЕЛО Ab2, СПОСОБ ЕГО ПОЛУЧЕНИЯ, ИСПОЛЬЗОВАНИЯ ПРОТИВ БОЛЕЗНЕЙ, СОПРОВОЖДАЮЩИХСЯ ЭКСПРЕССИЕЙ Lewis Y6 АНТИГЕНА, И ДЛЯ ОЧИСТКИ ВАРИАНТА BR55-2 АНТИТЕЛА, ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКИЙ СОСТАВ
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
ATE255910T1 (de) * 1996-04-10 2003-12-15 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
HUP0002760A3 (en) 1997-05-12 2003-03-28 Aphton Corp Woodland Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
CN1441676B (zh) * 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
EP2168598A1 (de) * 2001-09-28 2010-03-31 Purdue Research Foundation Verfahren zur Behandlung mit Ligand-Immunogen-Konjugaten
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
DK1794586T3 (da) 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3624841A4 (de) 2017-06-15 2021-01-27 Cancer Advances, Inc., Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3235924T1 (de) * 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire Monoklonaler antikoerper
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4675287A (en) * 1984-07-26 1987-06-23 Scripps Clinic And Research Foundation Monoclonal antibody directed to human ganglioside GD2
ZA858371B (en) * 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
FR2577081B1 (fr) * 1985-02-01 1991-01-11 Enertec Procede et dispositif de calage en phase rapide d'un signal d'horloge
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
EP0232706A3 (de) * 1986-01-10 1988-11-30 Sloan-Kettering Institute For Cancer Research Blutgruppe-Antigen-Platte
EP0248147A3 (de) * 1986-03-04 1989-02-15 Sloan-Kettering Institute For Cancer Research Verfahren zur Bestimmung der Anwesenheit von Krebszellen

Also Published As

Publication number Publication date
CA1303980C (en) 1992-06-23
EP0285059B1 (de) 1994-11-09
EP0285059A2 (de) 1988-10-05
EP0285059A3 (en) 1989-03-15
DE3852054D1 (de) 1994-12-15
JPS63279169A (ja) 1988-11-16
DE3852054T2 (de) 1995-05-18
US4971792A (en) 1990-11-20

Similar Documents

Publication Publication Date Title
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
ATE94205T1 (de) Monoklonale antikoerper gegen melanoma-assoziierte antigene, hybridzellinien, die diese antikoerper produzieren, und ihre verwendung.
IL93840A0 (en) Novel monoclonal antibody to novel antigen associated with human tumors
FI912016L (fi) In vitro -menetelmä antigeenispesifisten ihmisen monoklonaalisten vasta-aineiden valmistamiseksi
EG19493A (en) Novel antibodies reactive with human carcinomas
DK69890D0 (da) Monoklonale antistoffer, der er reaktive med cachetin
DE69031410D1 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
FI925631A7 (fi) Monoklonaaliset vasta-aineet
EP0359063A3 (en) Antibody having high affinity to hapten as antigen and immunogen for obtaining the same
NO162179C (no) Monoklonale antistoffer for anvendelse in vitro.
FI893428A7 (fi) TNF-a:n in vitro ja in vivo toksisten ominaisuuksien eliminointi monoklonaalisilla vasta-aineilla ja niistä johdetuilla fragmenteilla
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
FI901791A7 (fi) Lymfosyyttien reaktivisuuden määrittäminen veressä olevien spesifistenantigeenien suhteen
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
ATE87941T1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
KR890700832A (ko) 그람 음성균의 항원 결정기와 결합하는 사람 단일클론성 항체
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
IT1239065B (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
DE3579808D1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time